⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 5, 2023Journal of Diabetes InvestigationOpen Access

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial

Takahiro Iijima Makoto Shibuya Yuzuru Ito Yasuo Terauchi

View Full Paper

Ask AI

Bookmark

Share

Abstract

Switching from once-daily liraglutide to once-weekly semaglutide 0.5 mg significantly improved glycemic control and body weight compared with switching to once-weekly dulaglutide 0.75 mg.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Iijima et al. (2023) studied this question.

synapsesocial.com/papers/69d941ed9a6164e50fa3c610 https://doi.org/10.1111/jdi.14000

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1GLP-1 receptor agonists: a review of head-to-head clinical studiesHuman Clinical Trial · 2014 · 282 citations
2Harnessing glucagon‐like peptide‐1 receptor agonists for the pharmacological treatment of overweight and obesityRCT · 2016 · 94 citations
3Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesRCT · 2016 · 7,617 citations
4Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesRandomized Controlled Trial · 2016 · 6,887 citations
5Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in <scp>J</scp> apanese patients with type 2 diabetes: a 26‐week randomized phase <scp>III</scp> studyRCT · 2015 · 96 citations

Exposure–response analyses of liraglutide 3.0 mg for weight management2016
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial2017
Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes2015
History of gastrointestinal symptoms with other glucose‐lowering agents is associated with gastrointestinal adverse events after imeglimin initiation: A retrospective real‐world studyJournal of Diabetes Investigation · 2026
Parasympathetic dysfunction assessed by deep‐breathing CVR ‐R is associated with early discontinuation of oral semaglutide in type 2 diabetes: A multicenter retrospective studyJournal of Diabetes Investigation · 2026

More from Journal of Diabetes Investigation